VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

@article{Carbone2010VeriStratCF,
  title={VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.},
  author={David Paul Carbone and Jonathon Salmon and Dean Billheimer and Heidi Chen and Alan Sandler and Heinrich Roder and Joanna Roder and Maxim Tsypin and Roy S. Herbst and Anne S. Tsao and Hai T. Tran and Thao P. Dang},
  journal={Lung cancer},
  year={2010},
  volume={69 3},
  pages={337-40}
}
We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and… CONTINUE READING